Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.596
Filtrar
1.
Am J Med Genet A ; 185(2): 579-583, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33251766

RESUMO

Several patients with beta-propeller protein-associated neurodegeneration (BPAN)/static encephalopathy with neurodegeneration in adulthood have been reported to present Rett syndrome (RTT)-like features. This report presents an individual with BPAN showing clinical features of RTT. Psychomotor delay and epilepsy onset were noted at 1 year, and regression began at 4 years. Screening of the methyl-CpG binding protein 2 (MECP2) did not show variants. At 22 years, basal ganglia iron deposits were found on magnetic resonance imaging (MRI), and the WD-domain repeat 45 gene (WDR45) variant was identified. Review of the literature showed that BPAN with RTT-like features is associated with more epileptic seizures and less deceleration of head growth, breathing irregularities, and cold extremities than classic RTT with MECP2 variants. These clinical presentations may provide clues for differentiating between these two disorders. However, both WDR45 and MECP2 should be screened in patients presenting a clinical picture of RTT without specific MRI findings of BPAN.


Assuntos
Encefalopatias/genética , Proteínas de Transporte/genética , Proteína 2 de Ligação a Metil-CpG/genética , Síndrome de Rett/genética , Adolescente , Adulto , Gânglios da Base/metabolismo , Gânglios da Base/patologia , Encefalopatias/complicações , Encefalopatias/diagnóstico por imagem , Encefalopatias/patologia , Criança , Pré-Escolar , Epilepsia Parcial Complexa/complicações , Epilepsia Parcial Complexa/diagnóstico por imagem , Epilepsia Parcial Complexa/genética , Epilepsia Parcial Complexa/patologia , Feminino , Predisposição Genética para Doença , Humanos , Lactente , Recém-Nascido , Ferro , Distúrbios do Metabolismo do Ferro/complicações , Distúrbios do Metabolismo do Ferro/diagnóstico por imagem , Distúrbios do Metabolismo do Ferro/genética , Distúrbios do Metabolismo do Ferro/patologia , Imageamento por Ressonância Magnética , Síndrome de Rett/complicações , Síndrome de Rett/diagnóstico por imagem , Síndrome de Rett/patologia , Adulto Jovem
2.
Int J Mol Sci ; 21(22)2020 Nov 20.
Artigo em Inglês | MEDLINE | ID: mdl-33233618

RESUMO

Epilepsy belongs to the most common and debilitating neurological disorders with multifactorial pathophysiology and a high level of drug resistance. Therefore, with the aim of searching for new, more effective, and/or safer therapeutics, we discovered a focused series of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant properties. We applied an optimized coupling reaction yielding several hybrid compounds that showed broad-spectrum activity in widely accepted animal seizure models, namely, the maximal electroshock (MES) test and the psychomotor 6 Hz (32 mA) seizure model in mice. The most potent anticonvulsant activity and favorable safety profile was demonstrated for compound 30 (median effective dose (ED50) MES = 45.6 mg/kg, ED50 6 Hz (32 mA) = 39.5 mg/kg, median toxic dose (TD50) (rotarod test) = 162.4 mg/kg). Anticonvulsant drugs often show activity in pain models, and compound 30 was also proven effective in the formalin test of tonic pain, the capsaicin-induced pain model, and the oxaliplatin (OXPT)-induced neuropathic pain model in mice. Our studies showed that the most plausible mechanism of action of 30 involves inhibition of calcium currents mediated by Cav1.2 (L-type) channels. Importantly, 30 revealed high metabolic stability on human liver microsomes, negligible hepatotoxicity, and relatively weak inhibition of CYP3A4, CYP2D6, and CYP2C9 isoforms of cytochrome P450, compared to reference compounds. The promising in vivo activity profile and drug-like properties of compound 30 make it an interesting candidate for further preclinical development.


Assuntos
Acetamidas/farmacologia , Analgésicos/farmacologia , Anticonvulsivantes/farmacologia , Epilepsia Parcial Complexa/tratamento farmacológico , Dor/tratamento farmacológico , Pirrolidinas/farmacologia , Convulsões/tratamento farmacológico , Acetamidas/síntese química , Analgésicos/síntese química , Animais , Anticonvulsivantes/síntese química , Canais de Cálcio Tipo L/genética , Canais de Cálcio Tipo L/metabolismo , Capsaicina , Citocromo P-450 CYP2C9/genética , Citocromo P-450 CYP2C9/metabolismo , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP2D6/metabolismo , Citocromo P-450 CYP3A/genética , Citocromo P-450 CYP3A/metabolismo , Modelos Animais de Doenças , Esquema de Medicação , Eletrochoque/métodos , Epilepsia Parcial Complexa/induzido quimicamente , Epilepsia Parcial Complexa/genética , Epilepsia Parcial Complexa/fisiopatologia , Formaldeído , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Masculino , Camundongos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Oxaliplatina , Dor/induzido quimicamente , Dor/genética , Dor/fisiopatologia , Pirrolidinas/síntese química , Teste de Desempenho do Rota-Rod , Convulsões/induzido quimicamente , Convulsões/genética , Convulsões/fisiopatologia , Relação Estrutura-Atividade
3.
World Neurosurg ; 144: e149-e155, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32791221

RESUMO

BACKGROUND: Tumors presenting with drug-resistant seizures are termed as long-term epilepsy-associated tumors (LEATs). LEATs are more common in the temporal lobe, occur predominantly in pediatric age, and focal neurological deficits are rare. In this article, we aim to highlight our surgical experience in terms of seizure outcome among LEATs and discuss the factors affecting outcome. METHODOLOGY: We have retrospectively analyzed all the operated cases of intra-axial brain tumors with seizures (2015-2019). The clinical and radiographic data were collected from the hospital record system. For comparison, 2 groups were made (group 1 with good seizure control, i.e., Engel 1; and group 2 poor seizure outcome, i.e., Engel 2 and 3). RESULTS: A total of 51 cases were included; the temporal lobe was the most common location (n = 27); 23 patients had seizure frequency of "more than 1 seizure per week." Focal unaware seizures/complex partial seizures were the most common type of seizures encountered (n = 28). At a mean follow-up of 39.60 months, 38 patients had Engel 1 (78.5%) outcome (35 cases [71.05%] had the seizure duration of ≤2 years). The median duration of symptoms (group 1, 25 months vs. group 2, 65 months) was significantly different (P = 0.002). On comparing patients with seizure duration, we found a statistically significant difference (P < 0.00001). CONCLUSION: A shorter duration of symptoms, younger age of the patient, partial/focal seizures, and gross total excision were predictors of a good seizure outcome. Histopathology of the tumor does not affect the outcome when one compares glioneuronal tumors with non-glioneuronal tumors.


Assuntos
Neoplasias Encefálicas/complicações , Epilepsia/etiologia , Convulsões/cirurgia , Adolescente , Adulto , Fatores Etários , Neoplasias Encefálicas/diagnóstico por imagem , Neoplasias Encefálicas/cirurgia , Criança , Epilepsias Parciais/complicações , Epilepsias Parciais/cirurgia , Epilepsia/diagnóstico por imagem , Epilepsia/cirurgia , Epilepsia Parcial Complexa/complicações , Epilepsia Parcial Complexa/cirurgia , Feminino , Humanos , Imageamento por Ressonância Magnética , Masculino , Procedimentos Neurocirúrgicos , Estudos Retrospectivos , Convulsões/etiologia , Resultado do Tratamento , Adulto Jovem
4.
ACS Chem Neurosci ; 10(12): 4854-4863, 2019 12 18.
Artigo em Inglês | MEDLINE | ID: mdl-31756074

RESUMO

Antiepileptic drugs (AEDs) are the primary agents prescribed for clinical management of limbic epilepsy. However, high incidence of pharmacoresistance and a limited armory of drugs for inhibiting the pathological progression of epilepsy pose major obstacles to managing epilepsy. Here, we investigated the effect of tetramethylpyrazine (TMP), the main bioactive alkaloid isolated from the oriental medicine Ligusticum chuanxiong Hort., against the epileptogenesis progression of acute hippocampal and corneal (6 Hz) electrical kindling models of TLE. TMP dose-dependently limited the progression of seizures and reduced the after-discharge duration (ADDs) in a hippocampal mouse kindling model. Mice treated with TMP (20, 50 mg/kg, i.p.) remained in stage 1 of epileptic progression for a protracted period, requiring additional stimulation to induce stages 2-5 epileptic phenotypes. TMP (50 mg/kg) also inhibited 6 Hz corneal kindling progression. In contrast, TMP did not reverse the phenotypes induced in a generalized seizures (GS) model, or the maximal electroshock (MES) or pentylenetetrazole (PTZ)-induced models of epilepsy. Furthermore, patch clamp recordings revealed no effect of TMP (10 µM) on CA1 hippocampal neurons' intrinsic properties but suppressed the (i) frequency of spontaneous excitatory post synaptic currents (sEPSCs), (ii) paired pulse ratio (PPR), and (iii) long-term potentiation (LTP) induction in the Schaffer collateral-CA1 pathway. TMP suppressed the activity of calcium, but not sodium, channels. Taken together, these results suggest that TMP has an antiepileptogenic effect, likely through suppression of excitatory synaptic transmission by its effects on inhibition of calcium channels; these traits distinguish TMP from currently available AEDs. As mice administered TMP did not show any neurologic impairment in the object recognition and open field tests, the data support further development of TMP as a promising treatment for epilepsy.


Assuntos
Anticonvulsivantes/uso terapêutico , Região CA1 Hipocampal/efeitos dos fármacos , Bloqueadores dos Canais de Cálcio/uso terapêutico , Epilepsia Parcial Complexa/tratamento farmacológico , Potenciais Pós-Sinápticos Excitadores/efeitos dos fármacos , Excitação Neurológica/efeitos dos fármacos , Pirazinas/uso terapêutico , Convulsões/tratamento farmacológico , Animais , Anticonvulsivantes/farmacologia , Ansiedade/tratamento farmacológico , Ansiedade/etiologia , Região CA1 Hipocampal/fisiopatologia , Bloqueadores dos Canais de Cálcio/farmacologia , Canais de Cálcio/efeitos dos fármacos , Convulsivantes/toxicidade , Progressão da Doença , Estimulação Elétrica , Eletrochoque/efeitos adversos , Comportamento Exploratório/efeitos dos fármacos , Comportamento Exploratório/fisiologia , Transporte de Íons/efeitos dos fármacos , Potenciação de Longa Duração/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Vias Neurais/efeitos dos fármacos , Pentilenotetrazol/toxicidade , Pirazinas/farmacologia , Reconhecimento Psicológico/efeitos dos fármacos , Reconhecimento Psicológico/fisiologia , Canais de Sódio/efeitos dos fármacos
5.
Neurology ; 93(3): e237-e251, 2019 07 16.
Artigo em Inglês | MEDLINE | ID: mdl-31197031

RESUMO

OBJECTIVE: Intensive genetic analysis was performed to reveal comprehensive molecular insights into hypothalamic hamartoma (HH). METHODS: Thirty-eight individuals with HH were investigated by whole exome sequencing, target capture-based deep sequencing, or single nucleotide polymorphism (SNP) array using DNA extracted from blood leukocytes or HH samples. RESULTS: We identified a germline variant of KIAA0556, which encodes a ciliary protein, and 2 somatic variants of PTPN11, which forms part of the RAS/mitogen-activated protein kinase (MAPK) pathway, as well as variants in known genes associated with HH. An SNP array identified (among 3 patients) one germline copy-neutral loss of heterozygosity (cnLOH) at 6p22.3-p21.31 and 2 somatic cnLOH; one at 11q12.2-q25 that included DYNC2H1, which encodes a ciliary motor protein, and the other at 17p13.3-p11.2. A germline heterozygous variant and an identical somatic variant of DYNC2H1 arising from cnLOH at 11q12.2-q25 were confirmed in one patient (whose HH tissue, therefore, contains biallelic variants of DYNC2H1). Furthermore, a combination of a germline and a somatic DYNC2H1 variant was detected in another patient. CONCLUSIONS: Overall, our cohort identified germline/somatic alterations in 34% (13/38) of patients with HH. Disruption of the Shh signaling pathway associated with cilia or the RAS/MAPK pathway may lead to the development of HH.


Assuntos
Dineínas do Citoplasma/genética , Hamartoma/genética , Doenças Hipotalâmicas/genética , Proteínas Associadas aos Microtúbulos/genética , Proteína Tirosina Fosfatase não Receptora Tipo 11/genética , Adolescente , Adulto , Criança , Pré-Escolar , Cílios , Epilepsias Parciais/fisiopatologia , Epilepsia Parcial Complexa/fisiopatologia , Feminino , Mutação em Linhagem Germinativa , Hamartoma/fisiopatologia , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Doenças Hipotalâmicas/fisiopatologia , Lactente , Recém-Nascido , Sistema de Sinalização das MAP Quinases , Masculino , Mutação , Polimorfismo de Nucleotídeo Único , Análise de Sequência de DNA , Transdução de Sinais , Sequenciamento do Exoma , Adulto Jovem
6.
Hum Exp Toxicol ; 38(3): 336-346, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30472898

RESUMO

Serotonin (5-hydroxytrytamine (5-HT)) plays an important role in experimental seizures. Recently, we reported the depletion of 5-HT by parachlorophynylalanine (PCPA) in whole brain to enhance 6-Hz psychomotor seizures in mice. In the present work, we investigated the effect of 5-HT depletion in cortex and hippocampus, brain regions relevant for epilepsy, on behavioral and ultra-structural changes following 6-Hz psychomotor seizures in mice. In addition, we studied the effect of sodium valproate (SVP) on behavioral, biochemical, and ultra-structural effects induced by 6 Hz. Behavioral changes induced by 6 Hz stimulation were characterized as the increased duration of Straub's tail, stun position, twitching of vibrissae, forelimb clonus, and increased rearing and grooming. PCPA administration further enhanced while SVP reduced these behaviors in mice. The 6-Hz psychomotor seizure induced ultra-structural changes in both cortex and hippocampus in mice treated with PCPA. Furthermore, PCPA administrations followed by 6Hz-induced seizures were accompanied by reduced hippocampal and cortical 5-HT. SVP attenuated the PCPA-induced ultra-structural changes and alterations of 5-HT content in the mouse brain. The study suggests the involvement of 5-HT in the 6 Hz psychomotor seizures and in the mechanisms of action of SVP against such seizures in mice.


Assuntos
Córtex Cerebral/metabolismo , Epilepsia Parcial Complexa/metabolismo , Hipocampo/metabolismo , Convulsões/metabolismo , Serotonina/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Córtex Cerebral/efeitos dos fármacos , Modelos Animais de Doenças , Estimulação Elétrica , Hipocampo/efeitos dos fármacos , Masculino , Camundongos , Ácido Valproico/farmacologia
7.
World Neurosurg ; 120: 337-342, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30223038

RESUMO

BACKGROUND: Ictal asystole (IA) and ictal bradycardia (IB) are mainly seen with temporal or frontal lobe epilepsy. Many patients with these conditions undergo cardiac pacemaker therapy but not epilepsy surgery. CASE DESCRIPTION: We report the case of a 15-year-old boy with IA and IB secondary to right posterior quadrant epilepsy (PoQE) who underwent right posterior quadrant disconnection, but not cardiac pacemaker implantation. He has remained free from daily epileptic seizures, IA, and IB for more than 6 months postoperatively. This is the first report of a radically treated case with IA and IB caused by PoQE. CONCLUSIONS: Both temporofrontal lobe epilepsy and PoQE caused the IA and IB. Because a cardiac pacemaker only addresses arrhythmia, not epileptic seizures, radical treatment for both epilepsy and arrhythmia may be warranted for patients with medically intractable epilepsy.


Assuntos
Bradicardia/etiologia , Dominância Cerebral/fisiologia , Epilepsias Parciais/complicações , Epilepsia Parcial Complexa/complicações , Parada Cardíaca/etiologia , Adolescente , Bradicardia/fisiopatologia , Eletrocardiografia , Eletroencefalografia , Epilepsias Parciais/fisiopatologia , Epilepsias Parciais/cirurgia , Epilepsia Parcial Complexa/fisiopatologia , Epilepsia Parcial Complexa/cirurgia , Parada Cardíaca/fisiopatologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Malformações do Desenvolvimento Cortical/complicações , Malformações do Desenvolvimento Cortical/fisiopatologia , Malformações do Desenvolvimento Cortical/cirurgia , Lobo Occipital/fisiopatologia , Lobo Occipital/cirurgia , Cuidados Pós-Operatórios , Gravação em Vídeo
8.
Stereotact Funct Neurosurg ; 96(4): 259-263, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30149389

RESUMO

BACKGROUND: Neuromodulatory applications such as vagus nerve stimulation (VNS) and responsive neurostimulation (RNS) are safe and effective strategies for medically intractable epilepsy secondary to complex partial seizures, but researchers have yet to compare their efficacies. OBJECTIVE: The goal of this study is to compare VNS and RNS efficacy at reducing seizure frequency and complication rates in subjects with medically intractable epilepsy secondary to complex partial seizures. METHODS: This is a retrospective chart review of 30 patients with medically intractable complex partial epilepsy, who underwent either VNS or RNS placement at a single institution between June 2012 and January 2016. There was a mean follow-up of 19 months. Seizure frequency reduction and complications were identified. RESULTS: The median seizure frequency reduction was similar for VNS (66%) and RNS (58%). There was no major morbidity or mortality, and the frequency of minor complications was similar between VNS (15%) and RNS (18%). CONCLUSION: We found that VNS and RNS reduced the median seizure frequency similarly with no difference in morbidity or mortality. Further prospective studies are warranted as VNS and RNS therapy improves over time.


Assuntos
Epilepsia Resistente a Medicamentos/terapia , Terapia por Estimulação Elétrica/métodos , Epilepsia Parcial Complexa/terapia , Estimulação do Nervo Vago/métodos , Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
10.
Mol Genet Genomic Med ; 6(2): 282-287, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-29271071

RESUMO

BACKGROUND: Several genes have been implicated in a highly variable presentation of developmental delay with psychomotor retardation. Mutations in EMC1 gene have recently been reported. Herein, we describe a proband born of a consanguineous marriage, who presented with early infantile onset epilepsy, scaphocephaly, developmental delay, central hypotonia, muscle wasting, and severe cerebellar and brainstem atrophy. METHODS: Genetic testing in the proband was performed using custom clinical exome and targeted next-generation sequencing. This was followed by segregation analysis of the variant in the parents by Sanger sequencing and evaluation of the splice variant by RNA sequencing. RESULTS: Clinical exome sequencing identified a novel homozygous intronic splice variant in the EMC1 gene (chr1:19564510C>T, c.1212 + 1G>A, NM_015047.2). Neither population databases (ExAC and 1000 genomes) nor our internal database (n = 1,500) had reported this rare variant, predicted to affect the splicing. RNA sequencing data from the proband confirmed aberrant splicing with intron 11 retention, thereby introducing a stop codon in the resultant mRNA. This nonsense mutation is predicted to result in the premature termination of protein synthesis leading to loss of function of the EMC1 protein. CONCLUSION: We report, for the first time the role of aberrant EMC1RNA splicing as a potential cause of disease pathogenesis. The severe epilepsy observed in our study expands the disease-associated phenotype and also emphasizes the need for comprehensive screening of intronic splice mutations.


Assuntos
Epilepsia Parcial Complexa/genética , Proteínas da Matriz Extracelular/genética , Processamento Alternativo , Atrofia/genética , Doenças Cerebelares/genética , Doenças Cerebelares/patologia , Pré-Escolar , Consanguinidade , Exoma , Proteínas da Matriz Extracelular/metabolismo , Variação Genética , Homozigoto , Humanos , Íntrons , Masculino , Linhagem , Splicing de RNA/genética , Transtornos da Visão/genética , Sequenciamento do Exoma/métodos
11.
PLoS One ; 12(8): e0183873, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28859122

RESUMO

Accumulating evidence indicates that cannabinoid CB1 receptor ligands play a pivotal role in seizures, not only in preclinical studies on animals, but also in clinical settings. This study was aimed at characterizing the influence of arachidonyl-2'-chloroethylamide (ACEA-a selective cannabinoid CB1 receptor agonist) co-administered with phenylmethylsulfonyl fluoride (PMSF) on the anticonvulsant potency of various antiepileptic drugs (clobazam, lacosamide, levetiracetam, phenobarbital, tiagabine and valproate) in the 6-Hz corneal stimulation model. Psychomotor seizures in male albino Swiss mice were evoked by a current (32 mA, 6 Hz, 3 s stimulus duration) delivered via corneal electrodes. Potential adverse effects produced by the antiepileptic drugs in combination with ACEA+PMSF were assessed using the chimney test (motor performance), passive avoidance task (remembering and acquisition of learning), and grip-strength test (muscular strength). Brain concentrations of antiepileptic drugs were measured by HPLC to exclude any pharmacokinetic contribution to the observed effect. ACEA (5 mg/kg, i.p.) + PMSF (30 mg/kg, i.p.) significantly potentiated the anticonvulsant potency of levetiracetam (P<0.05), but not that of clobazam, lacosamide, phenobarbital, tiagabine or valproate in the 6-Hz corneal stimulation model. Moreover, ACEA+PMSF did not significantly affect total brain concentrations of levetiracetam in mice. No behavioral side effects were observed in animals receiving combinations of the studied antiepileptic drugs with ACEA+PMSF. In conclusion, the combined administration of ACEA+PMSF with levetiracetam is associated with beneficial anticonvulsant pharmacodynamic interaction in the 6-Hz corneal stimulation model. The selective activation of cannabinoid CB1 receptor-mediated neurotransmission in the brain may enhance levetiracetam-related suppression of seizures in epilepsy patients, contributing to the efficacious treatment of epilepsy in future.


Assuntos
Anticonvulsivantes/farmacologia , Ácidos Araquidônicos/farmacologia , Epilepsia Parcial Complexa/tratamento farmacológico , Fluoreto de Fenilmetilsulfonil/farmacologia , Piracetam/análogos & derivados , Receptor CB1 de Canabinoide/agonistas , Acetamidas/farmacologia , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Benzodiazepinas/farmacologia , Clobazam , Córnea , Modelos Animais de Doenças , Sinergismo Farmacológico , Quimioterapia Combinada , Eletrochoque/métodos , Epilepsia Parcial Complexa/metabolismo , Epilepsia Parcial Complexa/fisiopatologia , Lacosamida , Levetiracetam , Masculino , Camundongos , Força Muscular/efeitos dos fármacos , Ácidos Nipecóticos/farmacologia , Fenobarbital/farmacologia , Piracetam/farmacologia , Desempenho Psicomotor/efeitos dos fármacos , Tiagabina , Ácido Valproico/farmacologia
12.
Neurología (Barc., Ed. impr.) ; 32(5): 284-289, jun. 2017. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-163624

RESUMO

Introducción: El estatus epiléptico es una urgencia neurológica asociada a una mortalidad y morbilidad significativa. Analizamos las características en nuestra población. Métodos: Se recogieron los datos de manera retrospectiva de la historia clínica electrónica de adultos con diagnóstico de estatus epiléptico en 5 centros hospitalarios durante 4 años. Resultados: Se obtuvieron datos de un total de 84 episodios en 77 pacientes, con edad media de 60,3 años. El 52,4% tenían historia previa de epilepsia. Clasificación según el tipo de estatus: 47,6% tónico-clónico; 21,4% parcial complejo; 17,9% parcial motor; 6% parcial simple; 3,6% mioclónico y 3,6% sutil. Si analizamos el momento que finalizó el estatus según las fases definidas para este estudio obtenemos: 13,1% precoz (hasta 30 min); 20,2% establecido (entre 30-120 min); 41,7% refractario (más de 120 min) y 13,1% superrefractario (continúan o recurren después de más de 24 h de anestesia). Diez casos (11,9%) fallecieron sin haberse controlado el estatus. El porcentaje acumulativo de éxito alcanzado con el primer tratamiento fue de 8,3%; segundo 27,3%; tercero 48,7%; cuarto 58,2%; quinto 70,1%; sexto 80,8%; séptimo 83,2% y octavo 84,4%. Conclusiones: En nuestro estudio encontramos que el estatus no se controló en las primeras 2 h en casi la mitad de los casos, y un 11,9% fallecieron sin controlarse, sin haber diferencias significativas entre el tipo de estatus. En casi la mitad se logró el control del estatus con el tercer tratamiento, pero en algún caso se precisó hasta 8. Son necesarios registros amplios que permitan analizar el manejo en los distintos tipos y fases (AU)


Introduction: Status epilepticus (SE) is a neurological emergency associated with significant mortality and morbidity. We analyse characteristics of this entity in our population. Methods: Data from electronic medical records of adults diagnosed with SE were collected retrospectively from 5 hospitals over 4 years. Results: Data reflected 84 episodes of SE in 77 patients with a mean age of 60.3 years. Of this sample, 52.4% had a previous history of epilepsy. Status classification: 47.6% tonic-clonic, 21.4% complex partial, 17.9% partial motor, 6% partial simple, 3.6% myoclonic, and 3.6% subtle SE. Based on the duration of the episode, SE was defined in this study as early stage (up to 30 min) in 13.1%, established (30-120 min) in 20.2%, refractory (more than 120 min) in 41.7%, and super-refractory (episodes continuing or recurring after more than 24h of anaesthesia) in 13.1%. Ten patients (11.9%) died when treatment failed to control SE. The cumulative percentage of success achieved was 8.3% with the first treatment, 27.3% for the second, 48.7% for the third, 58.2% for the fourth, 70.1% for the fifth, 80.8% for the sixth, 83.2% for the seventh, and 84.4% for the eighth. Conclusions: In our study, we found that SE did not respond to treatment within 2h in approximately half the cases and 11.9% of the patients died without achieving seizure control, regardless of the type of status. Half the patients responded by the third treatment but some patients needed as many as 8 treatments to resolve seizures. Using large registers permitting analysis of the different types and stages of SE is warranted (AU)


Assuntos
Humanos , Estado Epiléptico/tratamento farmacológico , Convulsões/tratamento farmacológico , Epilepsia Parcial Complexa/tratamento farmacológico , Epilepsia Motora Parcial/tratamento farmacológico , Estudos Retrospectivos , Indicadores de Morbimortalidade , Anticonvulsivantes/uso terapêutico
14.
World Neurosurg ; 104: 467-475, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28502693

RESUMO

OBJECTIVE: Laser interstitial thermal therapy has become increasingly popular for targeting epileptic foci in a minimally invasive fashion. Despite its use in >1000 patients, the long-term effects of photothermal injury on brain physiology remain poorly understood. METHODS: We prospectively followed clinical and radiographic courses of 13 patients undergoing laser ablation for focal epilepsy by the senior author (N.T.). Only patients with nonenhancing lesions and patients who had a delayed postoperative magnetic resonance imaging (MRI) scan with gadolinium administration approximately 6 months after ablation were considered. Volumetric estimates of the amount of enhancement immediately after ablation and on the delayed MRI scan were made. RESULTS: Median interval between surgery and delayed postoperative MRI scan was 6 months (range, 5-8 months). In 12 of 13 cases, persistent enhancement was seen, consistent with prolonged blood-brain barrier dysfunction. Enhancement, when present, was 9%-67% (mean 30%). There was no correlation between the time from surgery and the relative percentage of postoperative enhancement on MRI. The blood-brain barrier remained compromised to gadolinium contrast for up to 8 months after thermal therapy. There were no adverse events from surgical intervention; however, 1 patient developed delayed optic neuritis. CONCLUSIONS: Prolonged incompetence of the blood-brain barrier produced by thermal ablation may provide a path for delivery of macromolecules into perilesional tissue, which could be exploited for therapeutic benefit, but rarely it may result in autoimmune central nervous system inflammatory conditions.


Assuntos
Barreira Hematoencefálica/fisiologia , Epilepsia Resistente a Medicamentos/fisiopatologia , Epilepsia Resistente a Medicamentos/cirurgia , Epilepsias Parciais/fisiopatologia , Epilepsias Parciais/cirurgia , Epilepsia Parcial Complexa/fisiopatologia , Epilepsia Parcial Complexa/cirurgia , Epilepsia Motora Parcial/fisiopatologia , Epilepsia Motora Parcial/cirurgia , Epilepsia do Lobo Temporal/fisiopatologia , Epilepsia do Lobo Temporal/cirurgia , Hemianopsia/diagnóstico , Hemianopsia/fisiopatologia , Terapia a Laser/métodos , Neurite Óptica/diagnóstico , Neurite Óptica/fisiopatologia , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/fisiopatologia , Técnicas Estereotáxicas , Cirurgia Assistida por Computador/métodos , Adolescente , Adulto , Estudos de Coortes , Angiografia por Tomografia Computadorizada , Meios de Contraste , Feminino , Gadolínio , Humanos , Interpretação de Imagem Assistida por Computador , Terapia a Laser/instrumentação , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Cirurgia Assistida por Computador/instrumentação , Adulto Jovem
15.
World Neurosurg ; 103: 145-152, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28391021

RESUMO

INTRODUCTION: Implantation of responsive neurostimulation (RNS) system has been previously discussed in the literature but there is a paucity of data on target accuracy and the use of intraoperative imaging. We describe our experience with 8 patients using intraoperative computed tomography (iCT) during implantation of the NeuroPace RNS system. METHODS: A frame-based system was used. CT images were obtained and merged with preoperative magnetic resonance imaging and metabolic imaging studies to calculate target coordinates. An occipital entry point with a trajectory parallel to the hippocampus was planned. The leads were placed in the parahippocampal white matter circuitry. iCT images were obtained for immediate confirmation of lead accuracy. Images were computationally merged and superimposed on the magnetic resonance images and final coordinates of the distal contact were compared with the intended target. Targeting error was calculated in each axis as well as Euclidean distance. Preoperative and postoperative seizure frequency per month was used to evaluate outcomes. RESULTS: Fifteen occipitotemporal leads were placed in 8 patients. The vector error means in the x, y, and z planes were 0.57 mm ± 0.44 mm, 0.71 mm ± 0.84 mm, and 2.23 mm ± 1.43 mm, respectively. The mean Euclidean distance error was 2.63 mm ± 1.32 mm. The z axis was found to have a significantly higher error [F2,42 = 12.955; P = 0.001] when compared with the x or y axes. The median preoperative and postoperative seizure frequency per month was 3.4 and 0.78 seizures, respectively. CONCLUSIONS: Frame-based stereotactic implantation of the NeuroPace RNS system using iCT is feasible and allows for intraoperative target accuracy confirmation and correction.


Assuntos
Encéfalo/diagnóstico por imagem , Epilepsia Parcial Complexa/terapia , Neuroestimuladores Implantáveis , Implantação de Prótese/métodos , Adulto , Encéfalo/cirurgia , Feminino , Humanos , Cuidados Intraoperatórios , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neuronavegação , Procedimentos Neurocirúrgicos , Cuidados Pré-Operatórios , Técnicas Estereotáxicas , Cirurgia Assistida por Computador , Tomografia Computadorizada por Raios X
16.
Epilepsia ; 58(6): 1005-1014, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28387951

RESUMO

OBJECTIVE: Evaluate the seizure-reduction response and safety of brain-responsive stimulation in adults with medically intractable partial-onset seizures of neocortical origin. METHODS: Patients with partial seizures of neocortical origin were identified from prospective clinical trials of a brain-responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2-6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events. Additional analyses considered safety and seizure reduction according to lobe and functional area (e.g., eloquent cortex) of seizure onset. RESULTS: There were 126 patients with seizures of neocortical onset. The average follow-up was 6.1 implant years. The median percent seizure reduction was 70% in patients with frontal and parietal seizure onsets, 58% in those with temporal neocortical onsets, and 51% in those with multilobar onsets (last observation carried forward [LOCF] analysis). Twenty-six percent of patients experienced at least one seizure-free period of 6 months or longer and 14% experienced at least one seizure-free period of 1 year or longer. Patients with lesions on magnetic resonance imaging (MRI; 77% reduction, LOCF) and those with normal MRI findings (45% reduction, LOCF) benefitted, although the treatment response was more robust in patients with an MRI lesion (p = 0.02, generalized estimating equation [GEE]). There were no differences in the seizure reduction in patients with and without prior epilepsy surgery or vagus nerve stimulation. Stimulation parameters used for treatment did not cause acute or chronic neurologic deficits, even in eloquent cortical areas. The rates of infection (0.017 per patient implant year) and perioperative hemorrhage (0.8%) were not greater than with other neurostimulation devices. SIGNIFICANCE: Brain-responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including adults with seizures of neocortical onset, and those with onsets from eloquent cortex.


Assuntos
Córtex Cerebral/fisiopatologia , Estimulação Encefálica Profunda/métodos , Epilepsia Resistente a Medicamentos/fisiopatologia , Epilepsia Resistente a Medicamentos/terapia , Terapia por Estimulação Elétrica/métodos , Eletroencefalografia , Neocórtex/fisiopatologia , Adolescente , Adulto , Mapeamento Encefálico , Estimulação Encefálica Profunda/instrumentação , Terapia por Estimulação Elétrica/instrumentação , Eletrodos Implantados , Epilepsias Parciais/fisiopatologia , Epilepsias Parciais/terapia , Epilepsia Parcial Complexa/fisiopatologia , Epilepsia Parcial Complexa/terapia , Epilepsia Motora Parcial/fisiopatologia , Epilepsia Motora Parcial/terapia , Epilepsia Tônico-Clônica/fisiopatologia , Epilepsia Tônico-Clônica/terapia , Estudos de Viabilidade , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
17.
Neurol Neurochir Pol ; 51(2): 194-196, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28215696

RESUMO

BACKGROUND: The direct oral anticoagulant (DOAC) rivaroxaban, an oral Factor Xa inhibitor, is increasingly used as an alternative to vitamin-K-antagonists (VKAs). Absorption and elimination of DOACs are dependent on the permeability glycoprotein (P-gp) efflux transporter protein system, and DOACs are substrates of the hepatic cytochrome P 450 3A4 (CYP3A4) enzymes. Therefore, drug-interactions may occur when DOACs are administered with drugs affecting the activity of P-gp or CYP3A4 systems. Several antiepileptic drugs like carbamazepine are known to affect P-gp and CYP3A4-activity. CASE REPORT: A 55-year-old male was admitted because of pain and swelling of his right leg spontaneously since 2 days. He was under a therapy with 20mg rivaroxaban since 4 months because of an unprovoked venous thrombosis of his right leg. He had a history of poliomyelitis at age 6 months, structural epilepsy due to poly-microgyria with complex partial seizures with secondary generalization since age 6 years, why he was treated with carbamazepine (900mg/d). He reported to be highly adherent to his anticoagulant and antiepileptic medication. Anti-Xa activity was <20ng/ml according to a rivaroxaban calibrated anti-factor Xa assay. Therapy with rivaroxaban was stopped, and low-molecular-weight heparin, followed by phenprocoumon, was started. CONCLUSION: The combination of DOACs with carbamazepine, an inducer of P-gp and CYP3A4-activity, should be avoided since the anticoagulant effect is decreased. There is an urgent need to increase our knowledge and physicians' awareness about the potential of drug-drug interactions of DOACs.


Assuntos
Carbamazepina/efeitos adversos , Epilepsia Parcial Complexa/tratamento farmacológico , Rivaroxabana/efeitos adversos , Rivaroxabana/uso terapêutico , Trombose Venosa/induzido quimicamente , Trombose Venosa/tratamento farmacológico , Carbamazepina/uso terapêutico , Interações Medicamentosas , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva , Trombose Venosa/diagnóstico
18.
Epilepsia ; 58(3): 484-493, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-28166368

RESUMO

OBJECTIVE: The metabotropic glutamate receptor subtype 2 (mGlu2 ) possesses both orthosteric and allosteric modulatory sites, are expressed in the frontal cortex and limbic structures, and can affect excitatory synaptic transmission. Therefore, mGlu2 is a potential therapeutic target in the treatment of epilepsy. The present study seeks to evaluate the anticonvulsant potential of mGlu2 -acting compounds. METHODS: The anticonvulsant efficacy of two selective mGlu2 -positive allosteric modulators (PAMs) (JNJ-42153605 and JNJ-40411813/ADX71149) and one mGlu2/3 receptor agonist (LY404039) were evaluated alone and in combination with the antiseizure drug levetiracetam (LEV) in the mouse 6 Hz model. RESULTS: In the 6 Hz (32 mA stimulus intensity) model, median effective dose (ED50 ) values were determined for JNJ-42153605 (3.8 mg/kg), JNJ-40411813 (12.2 mg/kg), and LY404039 (10.9 mg/kg). At the 44 mA stimulus intensity, ED50 values were determined for JNJ-42153605 (5.9 mg/kg), JNJ-40411813 (21.0 mg/kg), LY404039 (14.1 mg/kg), and LEV (345 mg/kg). In addition, subprotective doses of each mGlu2 -acting compound, administered in combination with various doses of LEV, were able to shift the 6 Hz 44 mA ED50 for LEV by >25-fold. When JNJ-42153605 was administered at varying doses in combination with a single dose of LEV (10 mg/kg), the potency of JNJ-42153605 was increased 3.7-fold. Similarly, when a moderately effective dose of LEV (350 mg/kg) was administered in combination with varying doses of JNJ-40411813, the potency of JNJ-40411813 was increased approximately 14-fold. Plasma levels of JNJ-40411813 and LEV were not different when administered alone or in combination, suggesting that increases in potency are not due to pharmacokinetic effects. SIGNIFICANCE: These studies suggest a potential positive pharmacodynamic effect of mGlu2 -acting compounds in combination with LEV. If this effect is translated in a clinical setting, it can support a rational polypharmacy concept in treatment of epilepsy patients.


Assuntos
Anticonvulsivantes/uso terapêutico , Epilepsia Parcial Complexa/tratamento farmacológico , Fármacos Atuantes sobre Aminoácidos Excitatórios/uso terapêutico , Piracetam/análogos & derivados , Receptores de Glutamato Metabotrópico/metabolismo , Animais , Biofísica , Compostos Bicíclicos Heterocíclicos com Pontes/uso terapêutico , Óxidos S-Cíclicos/uso terapêutico , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Eletrochoque/efeitos adversos , Epilepsia Parcial Complexa/etiologia , Levetiracetam , Masculino , Camundongos , Piracetam/uso terapêutico , Piridinas/uso terapêutico , Teste de Desempenho do Rota-Rod , Comportamento Estereotipado/fisiologia , Triazinas/uso terapêutico
20.
Med Glas (Zenica) ; 14(1): 126-131, 2017 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-27917853

RESUMO

Aim To investigate influence of therapy with new generation antiepileptic drugs (AEDs) in fastening of posttraumatic epilepsy (PTE) remission comparing to therapy with standard AEDs, as well as the time to remission in the presence of psychiatric comorbidities. Methods The study was conducted during the 1988-2008 period and included 113 patients (47 females and 67 males) with PTE and 113 patients (93 females and 20 males) suffering from complex partial seizures (CPS) of temporal lobe origin. In both patient groups, epileptic seizure phenotype, brain magnetic resonance imaging (1.5 T and 3.0 T) and electroencephalogram were analyzed within 24 hours of epileptic seizure and after 5 years of treatment. Psychological testing was administered prior to therapy initiation. Results The patients treated with standard AEDs achieved remission in 82 (73%) cases as compared with 87 (77%) patients administered with a new generation AEDs; in the latter group, remission was achieved faster (1.85 vs. 1.6 months). In both patient groups, psychiatric comorbidity prolonged time to remission by 3.4 months. Conclusion Therapy with new generation AEDs enables achieving faster and complete remission in PTE patients.


Assuntos
Anticonvulsivantes/administração & dosagem , Epilepsia Parcial Complexa/tratamento farmacológico , Epilepsia Parcial Complexa/psicologia , Lobo Temporal/diagnóstico por imagem , Anticonvulsivantes/uso terapêutico , Comorbidade , Eletroencefalografia/métodos , Epilepsia Parcial Complexa/diagnóstico , Feminino , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Indução de Remissão , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...